Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Actavis Labs

Pharmaceutical intelligence for Actavis Labs with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
6
Assets
7

Recent signals(8)

RegulatoryAugust 3, 2026

FDA Accepts Supplement Application for Phentermine Hydrochloride and Topiramate

The FDA has accepted a supplemental application for Phentermine Hydrochloride and Topiramate submitted by Actavis Labs.

RegulatoryJuly 19, 2026

FDA Acceptance of Linaclotide ANDA Submission by Actavis Labs

The FDA has accepted the ANDA submission for Linaclotide by Actavis Labs.

RegulatoryJuly 12, 2026

FDA grants supplemental approval for Phentermine Hydrochloride and Topiramate

The FDA has granted supplemental approval for the combination of Phentermine Hydrochloride and Topiramate under application ANDA204982.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for Risperidone by Actavis Labs

The FDA has accepted a supplemental application for Risperidone submitted by Actavis Labs.

RegulatoryJune 26, 2026

FDA Approval Update for FIORICET with Codeine Supplement

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

RegulatoryJune 26, 2026

FDA Approval for Hydromorphone Hydrochloride Supplement by Actavis Labs

The FDA has approved a supplemental application for Hydromorphone Hydrochloride submitted by Actavis Labs.

RegulatoryJune 25, 2026

FDA Accepts Supplement for FIORICET with Codeine

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

StrategyJune 23, 2026

FDA Grants Approval for Eltrombopag Olamine ANDA208815

The FDA has granted approval for ANDA208815, a generic version of Eltrombopag Olamine by Actavis Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(7)

RegulatoryAugust 3, 2026

FDA Accepts Supplement Application for Phentermine Hydrochloride and Topiramate

The FDA has accepted a supplemental application for Phentermine Hydrochloride and Topiramate submitted by Actavis Labs.

RegulatoryJuly 19, 2026

FDA Acceptance of Linaclotide ANDA Submission by Actavis Labs

The FDA has accepted the ANDA submission for Linaclotide by Actavis Labs.

RegulatoryJuly 12, 2026

FDA grants supplemental approval for Phentermine Hydrochloride and Topiramate

The FDA has granted supplemental approval for the combination of Phentermine Hydrochloride and Topiramate under application ANDA204982.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for Risperidone by Actavis Labs

The FDA has accepted a supplemental application for Risperidone submitted by Actavis Labs.

RegulatoryJune 26, 2026

FDA Approval Update for FIORICET with Codeine Supplement

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

RegulatoryJune 26, 2026

FDA Approval for Hydromorphone Hydrochloride Supplement by Actavis Labs

The FDA has approved a supplemental application for Hydromorphone Hydrochloride submitted by Actavis Labs.

RegulatoryJune 25, 2026

FDA Accepts Supplement for FIORICET with Codeine

The FDA has accepted a supplemental application for FIORICET with Codeine from Actavis Labs.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Eltrombopag Olamine →
FDA →
FIORICET with Codeine →
Hydromorphone Hydrochloride →
Linaclotide →
Risperidone →
Topiramate →

Therapeutic areas

Antipsychotic →
Combination Therapy →
Gastroenterology →
Gastroenterology · Linaclotide →
Hematology →
Hematology · Thrombocytopenia →
Linaclotide →
Neurology →
Neurology · Pain Management →
Obesity →
Opioid →
Pain Management →
Pain Management · Opioid →
Psychiatry →
Psychiatry · Antipsychotic →
Thrombocytopenia →

Indications

Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.